Sun BioPharma Inc. and its wholly owned subsidiary, Sun BioPharma Pty. Ltd., is a next-generation biopharmaceutical company developing disruptive therapeutics for serious unmet medical needs. The company’s initial programs are aimed at diseases of the pancreas, including pancreatic cancer and pancreatitis. Sun BioPharma has scientific collaborations with pancreatic disease experts at Honor Health in Scottsdale, AZ, Cedars Sinai Medical Center in Los Angeles, the University of Minnesota, Mayo Clinic Scottsdale, the Austin Health Cancer Trials Centre and the Ashford Cancer Centre in Adelaide, Australia.
Sun BioPharma’s common stock is quoted on the OTCQB tier of the over-the-counter markets administered by OTC Markets Group, Inc. under the symbol SNBP.